Indeed, versican predominantly binds to HA in tumours and degradation of the HA matrix with PEGPH20 will act in part by altering versican and versikine distribution, with repercussions on myeloid and lymphocyte recruitment [132,227,228]. The gene discussed is VCAN; the disease is neoplasm.